Boston Scientific (NYSE:BSX) Given New $78.00 Price Target at Robert W. Baird

Boston Scientific (NYSE:BSX) had its target price cut by equities researchers at Robert W. Baird from $86.00 to $78.00 in a research note issued on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the medical equipment provider’s stock. Robert W. Baird’s target price would suggest a potential upside of 20.09% from the company’s current price.

A number of other analysts have also recently weighed in on BSX. National Bank Financial set a $115.00 target price on shares of Boston Scientific in a research note on Monday, February 2nd. Evercore decreased their target price on shares of Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $115.00 target price on shares of Boston Scientific in a research note on Monday, March 30th. Oppenheimer reduced their price objective on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a research note on Friday, January 16th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $97.00 price objective on shares of Boston Scientific in a research note on Monday, March 30th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $97.65.

Boston Scientific Stock Up 9.1%

Shares of BSX opened at $64.95 on Thursday. Boston Scientific has a one year low of $59.38 and a one year high of $109.50. The company has a market cap of $96.53 billion, a P/E ratio of 33.48, a P/E/G ratio of 0.92 and a beta of 0.78. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The firm has a 50 day simple moving average of $68.87 and a two-hundred day simple moving average of $86.16.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The business had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. During the same period in the previous year, the business earned $0.75 earnings per share. The company’s revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Research analysts forecast that Boston Scientific will post 3.45 EPS for the current fiscal year.

Insider Buying and Selling

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the sale, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.34% of the company’s stock.

Institutional Trading of Boston Scientific

A number of institutional investors have recently bought and sold shares of BSX. Norges Bank bought a new stake in Boston Scientific during the fourth quarter valued at $2,199,395,000. Parnassus Investments LLC boosted its position in Boston Scientific by 42,978.9% during the third quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock valued at $672,128,000 after acquiring an additional 6,868,459 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in Boston Scientific by 133.6% during the first quarter. Assenagon Asset Management S.A. now owns 10,057,936 shares of the medical equipment provider’s stock valued at $631,135,000 after acquiring an additional 5,751,760 shares during the last quarter. Egerton Capital UK LLP boosted its position in Boston Scientific by 223.7% during the third quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock valued at $518,660,000 after acquiring an additional 3,671,548 shares during the last quarter. Finally, Maverick Capital Ltd. acquired a new position in shares of Boston Scientific during the fourth quarter valued at about $280,735,000. Institutional investors own 89.07% of the company’s stock.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q1 beat and strong sales growth: Boston Scientific reported revenue up ~11.6% and adjusted EPS that matched/beat estimates, fueling optimism about underlying demand and prompting the initial rally. Boston Scientific announces results for first quarter 2026
• Positive Sentiment: Unusually heavy bullish options flow: Large volumes of call buying suggest speculative and institutional interest expecting further upside in the near term. Traders Purchase High Volume of Boston Scientific Call Options (NYSE:BSX)
• Positive Sentiment: Analysts keep conviction despite cuts: Several firms (Jefferies, Barclays) lowered price targets but kept Buy/Overweight calls, framing the guidance cut as a near-term reset rather than a call to sell. Balancing Near-Term Guidance Cuts With Long-Term Growth Drivers: Upholding a Buy on Boston Scientific
• Neutral Sentiment: Stifel trims expectations but keeps Buy: Stifel lowered its price target from $90 to $85 while maintaining a buy rating — a modest downward adjustment that signals cautious optimism. Stifel Nicolaus Has Lowered Expectations for Boston Scientific (NYSE:BSX) Stock Price
• Neutral Sentiment: Price-target resets across the street: Multiple banks cut targets (Barclays, Jefferies) to reflect the lower 2026 outlook, reducing upside numbers while still often keeping positive ratings — a mixed signal for medium-term momentum. Why Is Boston Scientific Stock Soaring Wednesday?
• Negative Sentiment: Guidance cut and lower 2026 profit forecast: Management trimmed FY2026 EPS and revenue guidance, which is the main driver of analyst revisions and investor caution. Boston Scientific cuts 2026 profit forecast, trims revenue growth view
• Negative Sentiment: Litigation overhang: Multiple law firms have filed/invited claims alleging misstatements tied to past disclosures, creating potential legal and settlement risk and an added source of volatility. BSX DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action – BSX
• Negative Sentiment: Near-term valuation pressure: Recent analyst downgrades and PT cuts have pushed the shares to new lows at points, reflecting increased caution about near-term growth. Boston Scientific (NYSE:BSX) Hits New 52-Week Low After Analyst Downgrade

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.